Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lianbio ADR (NQ: LIAN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lianbio ADR

< Previous 1 2 3 4 Next >
Dow Surges 250 Points; US Manufacturing PMI Tops Expectations
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 250 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.80% to 33,200.75 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
From LianBio
Via GlobeNewswire
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology
From LianBio
Via GlobeNewswire
LianBio: Q1 Earnings Insights
Via Benzinga
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From LianBio
Via GlobeNewswire
Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations
Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize... 
Via Talk Markets
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
From LianBio
Via GlobeNewswire
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
From LianBio
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all the latest news this morning! 
Via InvestorPlace
LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand
From LianBio
Via GlobeNewswire
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023
From LianBio
Via GlobeNewswire
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
From LianBio
Via GlobeNewswire
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
From LianBio
Via GlobeNewswire
LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
From LianBio
Via GlobeNewswire
LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China
From LianBio
Via GlobeNewswire
LianBio to Participate in Upcoming Investor Conferences
From LianBio
Via GlobeNewswire
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From LianBio
Via GlobeNewswire
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China
From LianBio
Via GlobeNewswire
LianBio Touts Positive Data From Bristol Myers-Partnered Heart Drug In Chinese Patients
LianBio (NASDAQ: LIAN) announced  
Via Benzinga
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
From LianBio
Via GlobeNewswire
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its... 
Via Benzinga
LianBio Promotes Pascal Qian to Chief Commercial Officer
From LianBio
Via GlobeNewswire
LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
From LianBio
Via GlobeNewswire
LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From LianBio
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Pfizer Opts In To LianBio Rights to Respiratory Syncytial Virus Candidate In Greater China
Via Benzinga
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity... 
Via Benzinga
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
From LianBio; Pfizer Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.